null
ChEBI ID: 38870
| Member | Definition | Class |
|---|---|---|
| chloroform | A one-carbon compound that is methane in which three of the hydrogens are replaced by chlorines. | chloroform |
| cyclopropane | A cycloalkane composed of three carbon atoms to form a ring. | cyclopropane |
| desflurane | desflurane | |
| ether | An ether in which the oxygen atom is linked to two ethyl groups. | diethyl ether |
| ethyl chloride | The simplest and least toxic member of the class of chloroethanes, that is ethane in which a single hydrogen is substituted by a chlorine. A colourless gas at room temperature and pressure (boiling point 12degreeC), it is used as a mild topical anaesthetic to numb the skin prior to ear piercing, skin biopsies, etc., and is also used in the treatment of sports injuries. It was formerly used in the production of tetraethyllead. | chloroethane |
| halothane | A haloalkane comprising ethane having three flouro substituents at the 1-position as well as bromo- and chloro substituents at the 2-position. | halothane |
| isoflurane | isoflurane | |
| methoxyflurane | An ether in which the two groups attached to the central oxygen atom are methyl and 2,2-dichloro-1,1-difluoroethyl. | methoxyflurane |
| nitrous oxide | A nitrogen oxide consisting of linear unsymmetrical molecules with formula N2O. While it is the most used gaseous anaesthetic in the world, its major commercial use, due to its solubility under pressure in vegetable fats combined with its non-toxicity in low concentrations, is as an aerosol spray propellant and aerating agent for canisters of 'whipped' cream. | dinitrogen oxide |
| sevoflurane | An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups. | sevoflurane |
| trichloroethylene | A member of the class of chloroethenes that is ethene substituted by chloro groups at positions 1, 1 and 2. | trichloroethene |
| Timeframe | Studies, Drugs with This Role(%) | All Drugs % |
|---|---|---|
| pre-1990 | 21,201 (40.60) | 18.7374 |
| 1990's | 8,326 (15.94) | 18.2507 |
| 2000's | 8,966 (17.17) | 29.6817 |
| 2010's | 9,622 (18.43) | 24.3611 |
| 2020's | 4,106 (7.86) | 2.80 |
| Publication Type | Studies, Drugs with this Role (%) | All Drugs (%) |
|---|---|---|
| Trials | 7,561 (11.17%) | 5.53% |
| Reviews | 2,661 (3.93%) | 6.00% |
| Case Studies | 3,265 (4.82%) | 4.05% |
| Observational | 167 (0.25%) | 0.25% |
| Other | 54,040 (79.83%) | 84.16% |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| activating transcription factor 6 | Homo sapiens (human) | Potency | 0.0012 | 1 | 1 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 37.6505 | 1 | 1 |
| caspase-1 isoform alpha precursor | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 25.0282 | 1 | 4 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 39.8107 | 1 | 1 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 65.7058 | 3 | 5 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 74.1981 | 2 | 2 |
| geminin | Homo sapiens (human) | Potency | 13.3359 | 1 | 1 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 27.0840 | 2 | 2 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 67.4753 | 1 | 3 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 125.8660 | 1 | 1 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 54.5312 | 1 | 1 |
| interleukin 8 | Homo sapiens (human) | Potency | 79.5523 | 1 | 2 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 28.1838 | 1 | 1 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 40.5334 | 1 | 1 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 70.9011 | 1 | 2 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 74.9780 | 1 | 1 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 68.0320 | 2 | 2 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 25.0999 | 1 | 1 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 1.7783 | 1 | 1 |
| progesterone receptor | Homo sapiens (human) | Potency | 68.0320 | 1 | 1 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 39.3643 | 2 | 4 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 44.4400 | 3 | 4 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 37.4406 | 3 | 3 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 39.8107 | 1 | 1 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 0.0063 | 1 | 1 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 0.0040 | 2 | 2 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 54.5312 | 1 | 1 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 14.0503 | 2 | 3 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 67.4753 | 1 | 3 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| Albumin | Homo sapiens (human) | IC50 | 2,900.0000 | 1 | 1 |
| Neuronal acetylcholine receptor subunit alpha-7 | Homo sapiens (human) | IC50 | 11.7000 | 1 | 1 |
| Neuronal acetylcholine receptor subunit beta-2 | Homo sapiens (human) | IC50 | 11.7000 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | IC50 | 8,150.0000 | 2 | 2 |